270 related articles for article (PubMed ID: 38731601)
1. Metabolic Rewiring in Cancer: Small Molecule Inhibitors in Colorectal Cancer Therapy.
Masci D; Puxeddu M; Silvestri R; La Regina G
Molecules; 2024 May; 29(9):. PubMed ID: 38731601
[TBL] [Abstract][Full Text] [Related]
2. New strategies for targeting glucose metabolism-mediated acidosis for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2018 Jan; 234(1):348-368. PubMed ID: 30069931
[TBL] [Abstract][Full Text] [Related]
3. Targeting Strategies for Glucose Metabolic Pathways and T Cells in Colorectal Cancer.
Wang G; Wang JJ; Guan R; Sun Y; Shi F; Gao J; Fu XL
Curr Cancer Drug Targets; 2019; 19(7):534-550. PubMed ID: 30360743
[TBL] [Abstract][Full Text] [Related]
4. The Circadian Clock Regulates Metabolic Phenotype Rewiring Via HKDC1 and Modulates Tumor Progression and Drug Response in Colorectal Cancer.
Fuhr L; El-Athman R; Scrima R; Cela O; Carbone A; Knoop H; Li Y; Hoffmann K; Laukkanen MO; Corcione F; Steuer R; Meyer TF; Mazzoccoli G; Capitanio N; Relógio A
EBioMedicine; 2018 Jul; 33():105-121. PubMed ID: 30005951
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy.
Nenkov M; Ma Y; Gaßler N; Chen Y
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200820
[TBL] [Abstract][Full Text] [Related]
6. The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies.
El Hassouni B; Granchi C; Vallés-Martí A; Supadmanaba IGP; Bononi G; Tuccinardi T; Funel N; Jimenez CR; Peters GJ; Giovannetti E; Minutolo F
Semin Cancer Biol; 2020 Feb; 60():238-248. PubMed ID: 31445217
[TBL] [Abstract][Full Text] [Related]
7. Lipidome in colorectal cancer.
Yan G; Li L; Zhu B; Li Y
Oncotarget; 2016 May; 7(22):33429-39. PubMed ID: 26967051
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer.
Camp ER; Patterson LD; Kester M; Voelkel-Johnson C
Cancer Biol Ther; 2017 Sep; 18(9):640-650. PubMed ID: 28686076
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Pathways Regulating Colorectal Cancer: A Potential Therapeutic Approach.
Zafari N; Velayati M; Damavandi S; Pourali G; Mobarhan MG; Nassiri M; Hassanian SM; Khazaei M; Ferns GA; Avan A
Curr Pharm Des; 2022; 28(36):2995-3009. PubMed ID: 36154599
[TBL] [Abstract][Full Text] [Related]
11. Lactate-related metabolic reprogramming and immune regulation in colorectal cancer.
Sun Q; Wu J; Zhu G; Li T; Zhu X; Ni B; Xu B; Ma X; Li J
Front Endocrinol (Lausanne); 2022; 13():1089918. PubMed ID: 36778600
[TBL] [Abstract][Full Text] [Related]
12. Harnessing impaired energy metabolism in cancer cell: small molecule- mediated ways to regulate tumorigenesis.
Govardhan KS; Ramyasri K; Kethora D; Ravishekar Y; Prasenjit M
Anticancer Agents Med Chem; 2011 Mar; 11(3):272-9. PubMed ID: 21434854
[TBL] [Abstract][Full Text] [Related]
13. Targeting cellular energy metabolism- mediated ferroptosis by small molecule compounds for colorectal cancer therapy.
Wang G; Wang JJ; Xu XN; Shi F; Fu XL
J Drug Target; 2022 Sep; 30(8):819-832. PubMed ID: 35481396
[TBL] [Abstract][Full Text] [Related]
14. Glutaminolysis as a target for cancer therapy.
Jin L; Alesi GN; Kang S
Oncogene; 2016 Jul; 35(28):3619-25. PubMed ID: 26592449
[TBL] [Abstract][Full Text] [Related]
15. Targeting metabolic reprogramming in KRAS-driven cancers.
Kawada K; Toda K; Sakai Y
Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837
[TBL] [Abstract][Full Text] [Related]
16. Targeting dysregulated lipid metabolism in the tumor microenvironment.
Kim DH; Song NY; Yim H
Arch Pharm Res; 2023 Dec; 46(11-12):855-881. PubMed ID: 38060103
[TBL] [Abstract][Full Text] [Related]
17. Metabolic targeting of malignant tumors: small-molecule inhibitors of bioenergetic flux.
Mathupala SP
Recent Pat Anticancer Drug Discov; 2011 Jan; 6(1):6-14. PubMed ID: 21110820
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract.
Sur S; Nakanishi H; Flaveny C; Ippolito JE; McHowat J; Ford DA; Ray RB
Cell Commun Signal; 2019 Oct; 17(1):131. PubMed ID: 31638999
[TBL] [Abstract][Full Text] [Related]
19. Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways.
Kahlert UD; Mooney SM; Natsumeda M; Steiger HJ; Maciaczyk J
Int J Cancer; 2017 Jan; 140(1):10-22. PubMed ID: 27389307
[TBL] [Abstract][Full Text] [Related]
20. Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer.
Li C; Zhang G; Zhao L; Ma Z; Chen H
World J Surg Oncol; 2016 Jan; 14(1):15. PubMed ID: 26791262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
